Floatz logo

Sxrn

Cachexia

Jiangsu Nutai Biologics Co., Ltdgene_therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Cachexia cohort.

Asset / SponsorPhaseRating
Ponsegromab
Pfizer
Phase 2/3BB
Anamorelin
Helsinn Therapeutics (U.S.), Inc
Phase 3BB
MEGESTROL ACETATE IMPURITY B
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3BB
Nanocrystalline Megestrol Acetate Suspension
Nanfang Hospital, Southern Medical University
Phase 3BB
Infliximab
Centocor, Inc.
Phase 3BB

View all 29 →

Same molecule, other indications

Sxrn is also rated in:

Cachexia-Anorexia SyndromeDormant
CC
Indicative ·
43 / 100
View asset →
Solid Tumor MalignanciesDormant
C
Indicative ·
39 / 100
View asset →
cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →